Take the fight to Big Pharma.

Let's cap credit-card interest rates, take the fight to Big Pharma, end exploitative forced labor, and rid politics of corporate money once and for all.

Hawley commits to confront Big Pharma.

Hawley Op-Ed: The Promise of Pro-Labor Conservatism - Josh Hawley
primary · speech · model gpt-5.4-mini

The latest lookback-window Senate-office releases from June 9-30, 2026 cover USPS, labor, rural hospitals, MLB, Planned Parenthood, and child-trafficking items, with no new pharmaceutical, PBM, or drug-pricing action shown on the page.

No concrete new Big Pharma/PBM/drug-pricing delivery appeared in Hawley's official press-release feed during the June 9-July 8, 2026 lookback window; the status remains unresolved beyond earlier actions.

unresolved same_term

Press Releases - Josh Hawley
secondary · model gpt-5.5 · confidence 72%

Hawley and Warren urged the FTC to issue a second interim report on PBMs and said PBMs had become vertically integrated conglomerates controlling the drug coverage and delivery chain.

This is concrete same-term oversight pressure on pharmacy benefit managers, including a request for federal investigative findings to support 119th Congress policy work. It advances the commitment but does not prove a completed policy result.

partial same_term A for effort

Hawley, Warren Call on FTC to Release Second PBM Report
secondary · model gpt-5.5 · confidence 87%

Hawley and Warren introduced the Patients Before Monopolies Act to bar PBM or insurer parent companies from owning pharmacy businesses and require divestiture within three years.

The PBM bill is a serious anti-consolidation drug-cost action taken after the 2024 election. Because the item shows introduction rather than enactment, it supports partial delivery/effort rather than full delivery.

partial unknown A for effort

Hawley, Warren Introduce Bipartisan Bill to Control PBMs, Put Patients First
secondary · model gpt-5.5 · confidence 84%

The bill text names Hawley as introducer and would deem FDA approval of mifepristone for abortion withdrawn while creating a federal tort against manufacturers for covered harms.

Hawley introduced legislation directly targeting a pharmaceutical product and manufacturer liability. This is concrete action against a drug company, but no enactment or final regulatory reversal is shown.

partial same_term A for effort

Safeguarding Women from Chemical Abortion Act bill text
secondary · model gpt-5.5 · confidence 86%

Hawley's office said his mifepristone bill gained three Senate cosponsors and would withdraw FDA approval for abortion use and let harmed women sue manufacturers.

The release shows continued coalition-building around the 2026 pharmaceutical-manufacturer bill. It is meaningful effort but still short of enacted law or completed agency action.

partial same_term A for effort

Hawley Bill Banning Chemical Abortion Drug Gains Momentum
secondary · model gpt-5.5 · confidence 84%

Hawley asked DOJ to investigate Danco Laboratories' FDA approval history, regulatory compliance, distribution pipeline, marketing practices, and safety-risk disclosures, and said his subcommittee had opened its own investigation.

This is a concrete oversight/enforcement request aimed at a pharmaceutical manufacturer. It supports partial delivery with serious effort, but the record does not show DOJ opened or completed the investigation.

partial same_term A for effort

Hawley Urges DOJ to Open Investigation into Chemical Abortion Drug Manufacturer
secondary · model gpt-5.5 · confidence 88%